Ivermectin has one of the more remarkable origin stories in modern medicine: it was isolated from a soil bacterium, Streptomyces avermitilis, discovered in Japanese soil and developed into a drug that has since prevented blindness and disability in millions of people affected by parasitic disease. That work earned William Campbell and Satoshi Ōmura a share of the 2015 Nobel Prize in Physiology or Medicine. It is a genuinely useful medicine — but usefulness in one setting does not automatically mean safety in every population. This article sets out what the pediatric, obstetric, lactation and geriatric evidence actually supports, and where it is thinner than confident online claims suggest.
What ivermectin is approved to treat, and why dosing is not one-size-fits-all
In the United States, oral ivermectin (brand name Stromectol, among generics) is FDA-approved for two conditions: intestinal strongyloidiasis and onchocerciasis (river blindness). Topical formulations are separately approved for head lice and for rosacea. Every approved use is dosed by body weight, typically a single oral dose of about 150 to 200 micrograms per kilogram, repeated on a schedule that depends on the parasite being treated.
Tablet strength varies by market. In the US, the standard tablet is 3 mg; in other countries, including India, a 12 mg tablet is common and became widely recognized internationally during the pandemic. Neither strength changes what the drug is — the difference is simply how much active drug is in one tablet, which changes how many tablets (or fractions of tablets) a given body weight requires. Choosing a dose by tablet count rather than by calculated weight-based dose is not how this drug is meant to be used, in adults or children, and it is one of the more common sources of accidental over- or under-dosing when people self-medicate without a clinician's guidance.
Ivermectin for children: what the pediatric data support
For approved indications, ivermectin has a substantial pediatric safety record built largely through decades of mass drug administration programs for onchocerciasis and lymphatic filariasis across Africa and Latin America, coordinated with organizations including the World Health Organization. These programs, and clinical studies embedded within them, generally support use in children weighing 15 kilograms or more, dosed at the same weight-based rate as adults.
Below that weight threshold, the safety and pharmacokinetic data are considerably sparser, which is why product labeling has historically urged caution in young or low-weight children. Some research groups, including investigators working with WHO-affiliated neglected tropical disease programs, have studied lower-weight dosing using pediatric-friendly approaches (such as dispersible or liquid formulations) to try to close this gap, since parasitic disease itself is a real threat to small children in endemic regions. But this remains an area of ongoing study rather than settled, broadly approved practice — and it applies to specific tropical-medicine indications, not to general-purpose use.
Two practical points matter most for parents: first, dosing must be calculated by weight, not guessed from an adult tablet's strength, whether that tablet is 3 mg or 12 mg; splitting or estimating adult doses for a child is not a safe substitute for a clinician-directed pediatric dose. Second, ivermectin is not approved, and has not been shown in controlled pediatric trials, to treat viral respiratory illness in children. Parents facing a sick child are almost always better served by an evaluation for the actual illness present than by reaching for an antiparasitic drug that was not studied for that purpose.
Ivermectin in pregnancy: caution grounded in real uncertainty
This is the population where the evidence is most clearly limiting rather than reassuring. Animal reproduction studies — in mice and rabbits, at doses well above typical human exposure — have shown teratogenic effects, including cleft palate, at high multiples of the human dose. That does not prove harm at ordinary human doses, but it is the kind of signal that appropriately makes regulators and clinicians cautious.
Human data come mostly from an unplanned but informative source: large onchocerciasis mass-treatment campaigns in Africa occasionally treated women who were, unknown to program staff, already pregnant. Observational analyses of these inadvertent exposures, reviewed by expert bodies including the Mectizan Expert Committee that oversees the donation program, have not shown a clear pattern of birth defects or pregnancy loss above baseline rates. That is somewhat reassuring, but it falls well short of the kind of controlled evidence that would let a clinician confidently call the drug safe in pregnancy. Precisely because of this gap, pregnant women are systematically excluded from these mass drug administration campaigns as standing policy, and current prescribing guidance treats pregnancy as a reason to avoid the drug unless a specific, serious infection — such as strongyloides hyperinfection syndrome, which can be life-threatening — makes the benefit clearly outweigh the unknown risk. That is a judgment for a treating physician to make with the mother, not a decision to make alone from an internet search. Protecting an unborn child's wellbeing, and the mother's, means erring toward the option with the clearer safety record whenever one exists.
Ivermectin while breastfeeding
Ivermectin does pass into breast milk, but in relatively small amounts. Concentrations measured in lactating women who have taken a therapeutic dose are generally well below the doses used when ivermectin is given directly to infants and young children for approved indications, which is one reason several international health bodies, including WHO guidance connected to filariasis and scabies control programs, have treated it as compatible with continued breastfeeding when the mother needs treatment. Manufacturer labeling remains more conservative, advising that a nursing mother's need for the drug be weighed against potential infant exposure, largely because dedicated lactation safety trials are limited rather than because a specific harm has been documented. In practice, this is exactly the kind of decision worth a short conversation with a physician or pediatrician rather than either automatic avoidance or automatic reassurance.
Ivermectin for older adults: fewer restrictions, more interactions to watch
Age itself is not a contraindication to ivermectin, and there is no separate weight-independent dose reduction built into labeling purely for being older. Where age matters is indirectly, through the things that tend to accumulate with age: multiple prescription medications, reduced hepatic reserve, and a higher burden of chronic disease.
Ivermectin is metabolized substantially by the liver, so clinicians weigh hepatic function before prescribing, and case reports and pharmacologic reviews have documented an enhanced anticoagulant effect when ivermectin is combined with warfarin, which matters more in a population where warfarin use is common. Because ivermectin can cross into the central nervous system more readily in anyone with a compromised blood-brain barrier, and because older adults are more likely to have conditions that affect that barrier, some clinicians are more watchful for neurologic side effects such as dizziness, tremor, or confusion in this group. None of this rules ivermectin out for older adults with an appropriate indication; it simply means the same principle applies here as everywhere in geriatric prescribing — a full medication review with one's own physician before starting, not a blanket rule.
A note on off-label use and self-medication
Much of the recent public interest in ivermectin, including interest in the 12 mg tablet specifically, arose from its off-label use against COVID-19. It is worth stating plainly: ivermectin is not FDA-approved for the prevention or treatment of COVID-19. Two of the more rigorous randomized controlled trials on the question — the TOGETHER trial, a Brazilian and Canadian collaboration published in the New England Journal of Medicine in 2022, and the NIH-funded ACTIV-6 trial published in JAMA the same year — both found no meaningful reduction in hospitalization, recovery time, or symptom burden with standard antiparasitic-range dosing compared with placebo. Earlier positive signals had come mainly from smaller or lower-quality studies, and some widely cited early reports were later found to have serious data problems. This does not erase ivermectin's genuine, well-established value against the parasites it was built to treat; it simply means the evidence does not currently support reaching for it, tablet strength notwithstanding, as a home remedy for a different disease. Responsible self-reliance means knowing a medicine's real evidence base — and knowing when the right form of preparedness is a phone call to your own doctor before you take anything, especially where children, pregnancy, or an elderly relative on several other medications are involved.
Key takeaway: Ivermectin has decades of solid evidence supporting its approved uses in children over 15 kg and in adults, but pregnancy, breastfeeding, and any off-label use call for a physician's individualized judgment rather than fixed rules based on tablet strength alone.